Biota Pharmaceuticals Inc (BOTA) 2.85 $BOTA
34% Drop in Biota Pharmaceutical, Inc.'s Stock Price: Law Firm Investigates on Behalf of Shareholders
PR Newswire - Mon May 12, 3:42PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating potential violations of federal securities laws on behalf of investors of Biota Pharmaceutical, Inc. (NYSE: BOTA). Biota Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of anti-infective products.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Biota Pharmaceuticals, Inc. (BOTA) To Contact The Firm
PR Newswire - Fri May 09, 8:42PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Biota Pharmaceuticals, Inc. ("Biota" or the "Company"
(NasdaqGS: BOTA).
Biota Provides Update on BARDA Contract for Laninamivir Octanoate
GlobeNewswire - Thu May 08, 6:08AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced that last night it received notice from the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to terminate its contract, which was supporting the development of laninamivir octanoate, for the convenience of the Government. The decision is a result of a recently concluded In-Process Review. No reasons for the termination for convenience were provided to the Company. The Company intends to immediately begin negotiating a final termination settlement with ASPR/BARDA with respect to the termination of the contract.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Biota Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
GlobeNewswire - Tue May 06, 3:24PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced its financial results for the three month and nine month periods ended March 31, 2014, and provided an update on recent corporate developments.
Biota Provides an Update on the Development of Laninamivir Octanoate
GlobeNewswire - Wed Apr 30, 9:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced that an interim update has been provided from the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) with respect to the Stop-Work Order the Company recently received from BARDA and its pending decision regarding a recent In Process Review (IPR) of its contract to support the development of laninamivir octanoate.
Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals collapsed 34% upon receiving a stop-work...
Gogo and Spirit Airlines are big market movers
AP - Tue Apr 29, 3:41PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biota Pharmaceuticals, Inc. - BOTA
PR Newswire - Tue Apr 29, 11:20AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Biota Pharmaceuticals, Inc. ("Biota" or the "Company" (NASDAQ: BOTA) (CUSIP: 090694100). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Biota Pharmaceuticals, Inc. Announces Upcoming Events
GlobeNewswire - Tue Apr 29, 5:00AM CDT
Management to Host Conference Call to Review Q3 Financial Results
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Bacterial Pneumonia Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxbl8g/bacterial) has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Bacterial Pneumonia - Companies Involved in Therapeutics Development - Paratek Pharmaceuticals, Inc. - Bayer AG - ImmuVen, Inc. - Biota Pharmaceuticals, Inc. - Humabs BioMed SA - Dong-A Socio Holdings Co Ltd Drug Profiles - amikacin - tedizolid phosphate - omadacycline tosylate - Gyrase Program - IMV-0123 - MAb Against S aureus For more information visit http://www.researchandmarkets.com/research/jxbl8g/bacterial
Biota Pharmaceuticals, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Feb 24, 3:50PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Biota Pharmaceuticals Reports Second Quarter 2013 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Feb 10, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments.
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Financial Results on February 10, 2014
GlobeNewswire - Mon Feb 03, 8:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of the over-allotment option increases the net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $23.3 million to approximately $26.9 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
34% Drop in Biota Pharmaceutical, Inc.'s Stock Price: Law Firm Investigates on Behalf of Shareholders
PR Newswire - Mon May 12, 3:42PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating potential violations of federal securities laws on behalf of investors of Biota Pharmaceutical, Inc. (NYSE: BOTA). Biota Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of anti-infective products.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In Biota Pharmaceuticals, Inc. (BOTA) To Contact The Firm
PR Newswire - Fri May 09, 8:42PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Biota Pharmaceuticals, Inc. ("Biota" or the "Company"
(NasdaqGS: BOTA). Biota Provides Update on BARDA Contract for Laninamivir Octanoate
GlobeNewswire - Thu May 08, 6:08AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced that last night it received notice from the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to terminate its contract, which was supporting the development of laninamivir octanoate, for the convenience of the Government. The decision is a result of a recently concluded In-Process Review. No reasons for the termination for convenience were provided to the Company. The Company intends to immediately begin negotiating a final termination settlement with ASPR/BARDA with respect to the termination of the contract. Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Biota Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Corporate Developments
GlobeNewswire - Tue May 06, 3:24PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month and nine month periods ended March 31, 2014, and provided an update on recent corporate developments. Biota Provides an Update on the Development of Laninamivir Octanoate
GlobeNewswire - Wed Apr 30, 9:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced that an interim update has been provided from the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) with respect to the Stop-Work Order the Company recently received from BARDA and its pending decision regarding a recent In Process Review (IPR) of its contract to support the development of laninamivir octanoate. Massive Swings: Biota Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Healthcare investors were presented with major movements in two small stocks today: Amicus Therapeutics popped almost 21% on strong phase 3 data for a Fabry disease drug, while Biota Pharmaceuticals collapsed 34% upon receiving a stop-work...
Gogo and Spirit Airlines are big market movers
AP - Tue Apr 29, 3:41PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biota Pharmaceuticals, Inc. - BOTA
PR Newswire - Tue Apr 29, 11:20AM CDT
Pomerantz LLP is investigating claims on behalf of investors of Biota Pharmaceuticals, Inc. ("Biota" or the "Company"
(NASDAQ: BOTA) (CUSIP: 090694100). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. Biota Pharmaceuticals, Inc. Announces Upcoming Events
GlobeNewswire - Tue Apr 29, 5:00AM CDT
Management to Host Conference Call to Review Q3 Financial Results
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Bacterial Pneumonia Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxbl8g/bacterial) has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Bacterial Pneumonia - Companies Involved in Therapeutics Development - Paratek Pharmaceuticals, Inc. - Bayer AG - ImmuVen, Inc. - Biota Pharmaceuticals, Inc. - Humabs BioMed SA - Dong-A Socio Holdings Co Ltd Drug Profiles - amikacin - tedizolid phosphate - omadacycline tosylate - Gyrase Program - IMV-0123 - MAb Against S aureus For more information visit http://www.researchandmarkets.com/research/jxbl8g/bacterial
Biota Pharmaceuticals, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Feb 24, 3:50PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Biota Pharmaceuticals Reports Second Quarter 2013 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Feb 10, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments. Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Financial Results on February 10, 2014
GlobeNewswire - Mon Feb 03, 8:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call. Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of the over-allotment option increases the net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $23.3 million to approximately $26.9 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. 
